Kisspeptin — Clinical Reference

**⚠ Educational reference only — not medical advice.** This article is for research and educational reference. Always consult your own physician before considering any peptide protocol. See the full Disclaimer at the end of this article. ## Introduction Kisspeptin is the protein product of the KISS1 gene, originally identified as a metastasis-suppressor and later recognized as the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Active fragments include kisspeptin-10, -13, -14, and -54, all sharing a common C-terminal decapeptide. Investigational in most jurisdictions. ## Mechanism of Action Binds the kisspeptin receptor (KISS1R, GPR54) on hypothalamic GnRH neurons. Receptor activation drives pulsatile GnRH release, which in turn drives pituitary LH and FSH secretion. Kisspeptin is upstream of every clinically familiar HPG agent. ## Research Indications Ovulation triggering (more physiologic alternative to hCG with substantially reduced OHSS risk in early studies), evaluation and treatment of hypothalamic amenorrhea, and characterization of central hypogonadism. ## Reconstitution Typical 1 mg lyophilized vial: add **1 mL of bacteriostatic water**, swirl gently. Final concentration **1000 mcg/mL (1 mg/mL)** — each 0.01 mL (1 unit on a U-100 insulin syringe) delivers 10 mcg. ## Dosing Protocol (research literature) Kisspeptin-10 plasma half-life is short (~4 minutes), so most research protocols use **IV bolus or short infusion**. Published research doses span widely (**1–100 mcg IV**) depending on endpoint. **Subcutaneous research protocols** use **50–200 mcg SC** with effects on LH evaluated 30–90 minutes post-dose. Home dosing is not standardized. ## Administration IV bolus or short infusion in research clinic settings. Subcutaneous into abdominal fat in ambulatory protocols. ## Storage & Handling Lyophilized: refrigerate (2–8°C); freeze (–20°C) for long-term storage beyond 30 days. Reconstituted: refrigerate; stable approximately **7–14 days** — kisspeptin is more proteolysis-sensitive than many other research peptides. Protect from light. ## Side Effects Favorable safety profile in published trials. Significantly lower OHSS rates than hCG in matched IVF cohorts. Adverse events are predominantly mild. ## Contraindications Pregnancy, lactation, hormone-sensitive malignancy, and any condition where HPG-axis downregulation rather than activation is therapeutic. ## Monitoring Baseline LH, FSH, estradiol/testosterone, prolactin, TSH. Ovulation-related protocols require serial ultrasound and estradiol surveillance per fertility-clinic standard of care. ## Disclaimer **This article is for informational and research-reference purposes only.** Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation. **Customers should do their own research and consult their own physician** before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make. The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.